Long-term rituximab lowers NMOSD relapse risk, eases disability
Off-label rituximab significantly reduces the risk of relapse and lessens disability in most NMOSD patients, a long-term study showed.| Neuromyelitis News
Diagnosing NMOSD typically involves a detailed medical history, a thorough clinical evaluation, and specialized imaging and laboratory tests.| Neuromyelitis News
Neuromyelitis optica spectrum disorder affects the optic nerve, spinal cord, and sometimes the brainstem, resulting in a number of symptoms.| Neuromyelitis News
Category archive page for News.| Neuromyelitis News
Off-label rituximab significantly reduces the risk of relapse and lessens disability in most NMOSD patients, a long-term study showed.| Neuromyelitis News
